Business · 27/10/20261 min read
Opinion/decision on a plan of investigation for paediatrics (PIP): Fasenra, Benralizumab, type of decision: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000253868
Summary
Opinion/decision on a PIP: Fasenra, Benralizumab, type of decision: PM: decision on the application for modification of an agreed PIP, therapeutic area: blood and lymphatic system disorder...
Original source language: EMA — Paediatric Investigation PlansOpen original release →